Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset

Trial Profile

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Urokinase (Primary) ; Alteplase
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms PROST
  • Most Recent Events

    • 18 Jan 2019 Last checked against ClinicalTrials.gov record.
    • 09 Jan 2019 Planned number of patients changed from 700 to 680.
    • 01 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top